Personal Profile

Professor, Doctoral Supervisor, Research Group Leader and Principal Investigator (PI), and a high-level overseas-return talents. He/she graduated with a master's degree from China Pharmaceutical University and a doctorate from Xiamen University respectively. Currently, he/she is a professor in the School of Medicine, Zhongshan University. Before joining Zhongshan University, he/she spent many years studying abroad, including postdoctoral research at Johns Hopkins University in the United States and a research faculty position at the University of Maryland. After being introduced back to China as part of the "Hundred Talents Plan" of Zhongshan University, he/she has been a full-time professor in the Department of Biochemistry at Zhongshan University School of Medicine for over 10 years. He/she has also been a visiting professor at the Medical School of the University of Geneva in Switzerland, supported by the China Scholarship Council for academic exchanges.

Professor Zhou Xingwang has served as the principal investigator for multiple research projects, including the National Natural Science Foundation Overseas Cooperation Fund, the 973 Program of the Ministry of Science and Technology, key projects of the Guangdong Provincial Natural Science Foundation, and general projects of the National Natural Science Foundation. He/she is also an expert reviewer for the National Natural Science Foundation, the Ministry of Science and Technology, and the Ministry of Education's science and technology awards, as well as a specially invited reviewer for international proteomics journals. As the first author or corresponding author, he/she has published original research papers in mainstream international academic journals such as Phytomedicine (2024), J Cancer Res & Clinical Oncology (2022), Int J of Oncology (2020), Molecular & Cellular Proteomics (2017), and J. Biol. Chem. (JBC). Details can be found on PubMed and in the representative papers. He/she has applied for multiple invention patents, among which two related to tumor immunotherapy have been authorized by the National Intellectual Property Administration in recent years.

Currently, the research in his/her laboratory focuses on the regulatory mechanisms of biological drugs (including traditional Chinese medicine natural products and microbial vaccines) targeting tumor stem cells and related tumor immunotherapy, as well as disease proteomics (the chronic infection mechanism of Toxoplasma gondii mediated by the interaction between Toxoplasma gondii and the host).

Research Directions

• The regulatory mechanisms of biological drugs (including traditional Chinese medicine natural products and microbial vaccines) targeting tumor stem cells and related tumor immunotherapy.
• Disease proteomics (the chronic infection mechanism of Toxoplasma gondii mediated by the interaction between Toxoplasma gondii and the host).

Academic Achievements
6 Representative Papers

1. ​Corresponding Author Research Paper: Zhu S, Qi M, Chen M, Lin J, Huang H, Deng L, Zhou XW*. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer. Phytomedicine. 2024, 128: 155377.
2. ​Corresponding Author Research Paper: Bahwal SA, Chen JJ, E L, Hao T, Chen J, Carruthers VB, Lai J, Zhou XW*. Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model. J Cancer Res Clin Oncol. 2022, 148(10):2743 - 2757.
3. ​Corresponding Author Research Paper: Hu S, Yao X, Hao Y, Pan A, Zhou XW*. 8-gingerol regulates colorectal cancer cell proliferation and migration through EGFR/STAT/ERK pathway. International Journal of Oncology, 2020, 56(1): 390 - 397.
4. ​Corresponding Author Research Paper: Yang Z, Hou Y, Hao T, Rho HS, Wan J, Luan Y, Gao X, Yao J, Pan A, Xie Z, Qian J, Liao W, Zhu H, Zhou XW*. A human proteome array approach to identifying key host proteins targeted by Toxoplasma kinase ROP18. Mol & Cell Proteomics. 2017, 16(3), 469 - 484. (JCR Q1 authoritative journal).
5. ​First Author Paper: Zhou XW, Kafsack BF, Cole RN, Beckett P, Shen RF, Carruthers VB. The opportunistic pathogen Toxoplasma gondii deploys a diverse legion of invasion and survival proteins. Journal of Biological Chemistry, 2005, 280(40): 34233 - 34244.
6. ​First Author Paper: Zhou XW, Blackman MJ, Howell SA, Carruthers VB. Proteomic analysis of cleavage events reveals a dynamic two-step mechanism for proteolysis of a key toxoplasma adhesive complex. Molecular & Cellular Proteomics. 2004, 3(6): 565 - 76.